ALXO
HEALTHCAREAlx Oncology Holdings Inc
$2.09+0.16 (+8.29%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ALXO Today?
No stock-specific AI insight has been generated for ALXO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.40$2.66
$2.09
Fundamentals
Market Cap$281M
P/E Ratio—
EPS$-1.90
Dividend Yield—
Dividend / Share—
ROE-1.5%
Profit Margin—
Debt / Equity—
Trading
Volume691K
Avg Volume (10D)—
Shares Outstanding134.6M
ALXO News
20 articles- ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 ExpressionYahoo Finance·May 7, 2026
- Favourable Signals For ALX Oncology Holdings: Numerous Insiders Acquired StockYahoo Finance·May 2, 2026
- ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026Yahoo Finance·Apr 30, 2026
- ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing RulesYahoo Finance·Apr 17, 2026
- bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?Yahoo Finance·Apr 16, 2026
- ALX Oncology Appoints Jeff Knight as Chief Development and Operating OfficerYahoo Finance·Apr 13, 2026
- ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDAYahoo Finance·Mar 18, 2026
- CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study DataYahoo Finance·Mar 17, 2026
- IBRX Stock Jumps on Progress in NK Cell Therapy ProductionYahoo Finance·Mar 16, 2026
- JNJ's Bladder Cancer Therapy Meets Key Goal in Early-Stage StudyYahoo Finance·Mar 16, 2026
- Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4Yahoo Finance·Mar 13, 2026
- ALX Oncology initiated with a Buy at UBSYahoo Finance·Mar 7, 2026
- LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?Yahoo Finance·Mar 6, 2026
- Mirum Completes Enrollment & Screening in Liver Disease StudiesYahoo Finance·Mar 6, 2026
- ALX Oncology Highlights $150M Raise, Evorpacept Breast Cancer Push and EGFR ADC ALX2004 UpdateMarketbeat·Mar 4, 2026
- ALX Oncology Holdings Inc (ALXO) Q4 2025 Earnings Call Highlights: Strong Clinical Progress and ...Yahoo Finance·Feb 27, 2026
- ALX Oncology Holdings Inc. Q4 2025 Earnings Call SummaryMoby·Feb 27, 2026
- ALX Oncology Q4 Earnings Call HighlightsMarketbeat·Feb 27, 2026
- ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Feb 27, 2026
- ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026Yahoo Finance·Feb 19, 2026
All 20 articles loaded
Price Data
Open$1.91
Previous Close$1.93
Day High$2.05
Day Low$1.91
52 Week High$2.66
52 Week Low$0.40
52-Week Range
$0.40$2.66
$2.09
Fundamentals
Market Cap$281M
P/E Ratio—
EPS$-1.90
Dividend Yield—
Dividend / Share—
ROE-1.5%
Profit Margin—
Debt / Equity—
Trading
Volume691K
Avg Volume (10D)—
Shares Outstanding134.6M
About Alx Oncology Holdings Inc
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. The company is headquartered in Burlingame, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—